Abstract
Candida auris, an emerging fungus that exhibits a unique transmission ability, causes large healthcare-associated outbreaks on 6 continents since first reported in 2009. Most isolates have acquired fluconazole resistance, and resistance to other agents/classes emerges during drug exposure. The emergence of C auris infections raises serious concerns for public health. Systematic elaboration on clinical treatment and prevention of C auris infections is rare. We aim to summarize the research progress on the risk factors, clinical signs, drug treatment and prevention of C auris infections.